Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers

Table 4 Variables association with overall survival, DFS, recurrence and metastasis

	n	Survival		DFS		Local recurrence		Metastasis
		%	P	%	P	%	P	%	P
Gender
Male	146	85.6	NS	78.1	< 0.05	5.5	NS	16.4	NS
Female	113	89.4		87.6		2.7		9.7
Tumor location			NS		NS		NS
High	62	88.7		85.5		3.2		12.9
Medium	115	87.8		83.5		6.1		10.4	NS
Low	82	85.4		80.5		2.4		18.3
Pathology			< 0.05		< 0.05		< 0.05
Adenocarcinoma	236	87.7		83.9		3.8		13.1
Mucinous cancer	18	94.4		83.3		5.6		11.1	NS
Signet ring cancer	5	40		40		20		40
Differentiation
High-medium	222	87.4	NS	82.9	NS	4.1	NS	13.1	NS
Low	37	86.5		78.4		5.4		16.2
TNM staging			< 0.05		< 0.05		< 0.05
I	80	95		92.5		1.3		6.3
II	67	92.5		89.6		1.5		9.0	< 0.05
III	112	78.6		70.3		8		21.4
Invasion depth			< 0.05		<0.05		NS
T1-2	101	95.0		91.1		2		6.9
T3	85	83.5		78.8		4.7		16.5	< 0.05
T4	73	80.8		75.3		6.8		19.2
N staging			< 0.05		< 0.05		< 0.05
N0	147	93.9		91.2		1.4		7.5	< 0.05
N1-2	112	78.6		72.3		8.0		21.4
Lymphvascular invasion			NS		NS		NS
+	33	81.8		78.8		6.1		15.2
-	226	88.1		83.6		4		13.3	NS
Neural invasion					NS		NS
+	21	85.7	NS	85.7		4.8		14.3
-	238	87.4		82.8		4.2		13.4	NS
Preoperative CEA			0.06		< 0.05		NS
+	48	20.8		31.3		6.3		25
-	211	10.9		14.7		3.8		10.9	< 0.05
P53			NS		NS
+	118	84.4		80.9		6.4	0.06	13.5	NS
-	141	90.7		85.6		1.7		13.6
P21			NS		NS		NS
+	209	87.6		81.8		4.3		13.9	NS
-	50	86		84		4.0		12.0
PCNA			NS		NS		NS	12.6
+	159	89.3		84.3		3.1		15.0	NS
-	100	84.0		81.0		6.0
CD44			< 0.05		< 0.05		NS
+	129	82.9		76.7		6.2		17.1	0.97
-	130	91.5		87.8		2.3		10.0

NS: not significant.